Press Releases

Press Releases

These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools.

Nov 15, 2017
LEXINGTON, Mass., Nov. 15, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced the receipt of a $4 million payment for the advancement of an undisclosed antibody under the license
Nov 08, 2017
LEXINGTON, Mass., Nov. 8, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced today that Jennifer Buell, Ph.D., Chief Communications and External Affairs Officer at Agenus, and Michael Plater,
Oct 23, 2017
Bruno Lucidi, previously of Idenix, Pharmasset and BMS named AgenTus CEO LEXINGTON, Mass., Oct. 23, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced the launch of a subsidiary
Sep 19, 2017
LEXINGTON, Mass., Sept. 19, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immune-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced today that members of the Company's Leadership will present and host one-on-one meetings at two healthcare
Jun 21, 2017
LEXINGTON, Mass., June 21, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, invites investors and the general public to its Annual Meeting of Stockholders to begin at 5:00 p.m.
Jun 05, 2017
LEXINGTON, Mass., June 5, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced the results from an ongoing Phase 1 dose-escalation trial for its anti-CTLA-4 antibody, AGEN1884, in patients